Calgary, Alberta, Canada / TheNewswire / March 26, 2024 - Voyageur Pharmaceuticals Ltd . ( TSX.V: VM ) (USA: VYYRF) (" Voyageur " or the " Company "), announces that it has filed its annual audited financial statements and management's discussion and analysis for the year ended November 30, 2023 on SEDAR+. Option Grant Voyageur also announces that it has granted 3,700,000 stock options (the " Options ") to directors,... Read More

Voyageur Pharmaceuticals Ltd . ( TSX.V: VM ) (USA: VYYRF) ("Voyageur" or the "Corporation"), announces a significant advancement in its partnership with Rain Cage Carbon Inc. ("Rain Cage"). This milestone signifies the execution of a royalty agreement that solidifies the exclusive development and license agreement between the parties and it further reinforces Voyageur’s commitment to pioneering sustainable carbon drug... Read More

Voyageur Pharmaceuticals Ltd . (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the "Corporation") and Applied Pharmaceutical Innovation (API), a leading industry-funded not-for-profit organization driving life sciences commercialization, proudly announce the signing of a Master Services Agreement ( MSA ). This collaboration represents a significant advancement in both entities’ commitment to innovation, heralding a transformative... Read More

Calgary, Canada / TheNewswire / March 1, 2024 - Voyageur Pharmaceuticals Ltd . ( TSX.V:VM ) (USA:VYYRF) ("Voyageur" or the "Company"), a provider of innovative medical imaging solutions, is pleased to announce it has closed its previously announced (January 16, 2024) non-brokered private placement (the "Offering") of units ("Units") sold at a price of $0.08 per Unit. Pursuant to the Offering, the Company issued 6,106,250... Read More

Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) (USA:VYYRF) ("Voyageur" or the "Company"), a provider of innovative medical imaging solutions, is pleased to announce a proposed non-brokered private placement of up to 10,000,000 units ("Units") at a price of $0.08 per Unit, for gross proceeds of up to CND$800,000 (the "Offering"). Each Unit shall be comprised of one common share in the capital of the Company (each, a "Common... Read More

Calgary, Canada - TheNewswire - December 21, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (" Voyageur " or the " Corporation "), a provider of innovative medical imaging solutions, is excited to announce that its carbon capture and drug development partner, Rain Cage Carbon Inc. (“Rain Cage”), has successfully completed Stage 1 testing of a new molecule, metallofullerene, for the medical imaging industry. This... Read More

Voyageur Pharmaceuticals Ltd. ( TSX.V:VM ) (USA:VYYRF) (" Voyageur " or the " Corporation "), a provider of innovative medical imaging solutions, is pleased to announce the formalization of a pivotal sales and distribution alliance with an internationally recognized pharmaceutical distribution company in Central America. This landmark agreement marks a significant milestone in Voyageur's journey, signaling its entry into the... Read More

Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) ( USA : VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, is pleased to announce the completion of formulation and the engineering for production processing for the dry powdered barium contrast media product HDXBa TM . HDXBa TM is an oral contrast agent for suspension used as an oral drug for use in double-contrast radiographic... Read More

Calgary, Alberta - TheNewswire - August 1, 2023 - Voyageur Pharmaceuticals Ltd. ( TSX.V:VM ) ( USA: VYYRF ) (the " Company " or " Voyageur ") announces that it has filed its interim financial statements and management's discussion and analysis for the quarter ended May 31, 2023 on SEDAR+ (www.sedarplus.ca). Voyageur also announces the retirement from the Board of Directors of the Corporation (the " Board ") of Ron Sifton who... Read More

Calgary, Alberta - TheNewswire - July 13, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the " Company " or " Voyageur ") announces that on July 10, 2023, it issued 383,360 Deferred Share Units ("DSUs") to directors of the Company pursuant to its fixed 10% equity incentive compensation plan (the "Plan"). Each DSU represents a right of the holder to receive one common share ("Common Share") of the Company... Read More

Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) ( USA : VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, is pleased to announce the release of the white paper titled "SmoothX: A Promising New Positive Oral Contrast Agent for CT." Authored by Alec J. Megibow, MD, MPH, FACR, the white paper highlights the remarkable imaging properties of Voyageur's product, SmoothX™, emphasising its... Read More

Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) ( OTC :VYYRF) ("Voyageur" or the "Corporation"), announces it has entered into a groundbreaking development and license agreement with Rain Cage Carbon Inc. ("Rain Cage"). This strategic partnership aims to revolutionize the field by developing and manufacturing cutting-edge nanocarbon/fullerene-based contrast agents for medical imaging, utilizing Rain Cage’s innovative EDEN™ carbon... Read More

Calgary, AB - TheNewswire - April 28, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the " Company " or " Voyageur ") announces that it has filed its interim financial statements and management's discussion and analysis for the quarter ended February 28, 2023 on SEDAR. The Company also announces that on April 10, 2023, it issued 328,675 Deferred Share Units ("DSUs") to directors of the Company pursuant to its... Read More

Calgary, Alberta – TheNewswire - April 4, 2023 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the "Company" or "Voyageur") announces that it has completed comparative studies of SmoothX® versus Readi-Cat ® 2% with taste test and Computed Tomography (CT) scans on patients. Results of the double-blind testing showed that SmoothX® was favoured on drinkability and taste by 75% of patients compared to the competing... Read More

Calgary, AB - TheNewswire - March 30, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the "Company" or "Voyageur") announces that it has filed its annual audited financial statements and management's discussion and analysis for the year ended November 30, 2022 on SEDAR. The Company also announces that, due to a shortfall in spending on the Frances Creek project, because of closures to the site over the past... Read More

Calgary, Alberta – TheNewswire - February 14, 2023 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the "Company" or "Voyageur") continues to advance its sales and marketing programs and is preparing to launch its first product, SmoothX™ barium sulfate CT contrast media oral suspension for the CT imaging market, in Canada. Voyageur announced today that Ethan Mohan has joined the Company’s sales team as Canadian Sales... Read More

Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the " Company " or " Voyageur ") announces that, further to its news releases dated December 8 and 23, 2022 and January 12 and 20, 2023, the use of proceeds with respect to its increased non-brokered private placement of units of the Company (" Units ") at a price of $0.07 per Unit (the " Offering "), were incorrectly totalled. The gross proceeds received by Voyageur from... Read More

Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the " Company " or " Voyageur ") is pleased to announce that, further to its news releases dated December 8 and 23, 2022 and January 12, 2023, it has completed the second and final closing of its increased non-brokered private placement of units of the Company (" Units ") at a price of $0.07 per Unit (the " Offering "), issuing an aggregate of 14,570,764 Units for gross... Read More

News Release – TheNewswire - Calgary, Alberta – January 12, 2023: V oyageur Pharmaceuticals Ltd. (TSXV:VM) (USA: VYYRF) (the " Company " or " Voyageur ") is pleased to announce that, further to its news releases dated December 6 and 23, 2022, and due to strong investor demand for its non-brokered private placement of units of the Company (" Units ") at a price of $0.07 per Unit, it has increased the maximum size of the... Read More

News Release – Calgary, Alberta – TheNewswire - December 23, 2022: Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (the " Company " or " Voyageur ") is pleased to announce that, further to its news release dated December 6, 2022, it has completed the first closing of its non-brokered private placement of up to units of the Company (" Units ") for proceeds of up to CDN$650,000, with each Unit being sold at a price of... Read More

News Release – Calgary, Alberta – TheNewswire - December 8, 2022: Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the "Company" or "Voyageur") announces that it has initiated its marketing campaign to introduce SmoothX ™ barium sulfate CT contrast media, to the CT Imaging market in Canada. SmoothX is a generic oral barium sulfate contrast media product, designed to assist in diagnosing disease using computed tomography... Read More

Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) (the "Company" or "Voyageur") announces that it has issued 125,322 Deferred Share Units ("DSUs") to directors pursuant to its fixed 10% equity incentive compensation plan adopted by the Company following receipt of shareholder approval on June 28, 2021 (the "Plan"). Each DSU represents a right of the holder to... Read More

Calgary, Alberta – TheNewswire - November 28, 2022 : Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the "Company" or "Voyageur") announces completion of the production test batch of its SmoothX™ barium sulfate CT contrast media oral suspension for the CT imaging market in Canada. This development represents a significant transition for Voyageur from the development phase to the production phase, where the focus will... Read More